5 Results for "

CDK9-IN-13

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "CDK9-IN-13" in MCE Product Catalog:

Cat. No.: HY-139980
CAS No.: 2768712-71-4
Purity:  99.94%
Target:  

CDK

Research Areas:  

Cancer

CDK9-IN-13 (compound 38) is potent and selective CDK9 inhibitor, with an IC50 of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .
loading...
    loading...
Cat. No.: HY-184693
Research Areas:  

Cancer

PROTAC CDK9 degrader-13 is a selective CDK9 degrader acting via the ubiquitin-proteasome system. PROTAC CDK9 degrader-13 induces apoptosis in acute myeloid leukemia cells. PROTAC CDK9 degrader-13 suppresses tumor growth in vivo and has a defined safety profile. PROTAC CDK9 degrader-13 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-184694
Research Areas:  

Cancer

CDK9 ligand 6 is a PROTAC target protein ligand targeting CDK9, which can be used in research related to PROTAC synthesis, such as serving as the target protein ligand for PROTAC CDK9 degrader-13 (HY-184693) .
loading...
    loading...
Cat. No.: HY-184696
Research Areas:  

Cancer

Pomalidomide-C16-azide is a PROTAC E3 ligase ligand-linker conjugate that can be used in studies related to PROTAC synthesis, such as serving as the E3+linker structure of PROTAC CDK9 degrader-13 (HY-184693) .
loading...
    loading...
Cat. No.: HY-184695
CAS No.: 2755836-98-5
Research Areas:  

Cancer

NH2-C16-azide is a 16-azidohexadecylamine derivative and synthetic intermediate, which can serve as a PROTAC Linker. NH2-C16-azide is applicable to research related to PROTAC synthesis, such as acting as the linker for PROTAC CDK9 degrader-13 (HY-184693) .
loading...
    loading...